Past performance does not predict future results. Informational only, not investment advice.
Swenson Daren (EVP, Chief Corr & Reentry Ofcr at CoreCivic, Inc.) reported an open-market sale of 20,000 shares of CXW at an average $34.85, roughly $697,000, in a Form 4 filed 2026-09-11.
GARFINKLE DAVID (EVP & Chief Financial Officer at CoreCivic, Inc.) reported an open-market sale of 50,000 shares of CXW at an average $33.96, roughly $1,698,000, in a Form 4 filed 2026-08-21.
PRANN JOHN R JR (Director at CoreCivic, Inc.) reported an open-market sale of 22,298 shares of CXW at an average $34.00, roughly $758,132, in a Form 4 filed 2026-08-21.
PRANN JOHN R JR (Director at CoreCivic, Inc.) reported an open-market sale of 40,000 shares of CXW at an average $33.54, roughly $1,341,560, in a Form 4 filed 2026-08-18.
GARFINKLE DAVID (EVP & Chief Financial Officer at CoreCivic, Inc.) reported an open-market sale of 50,000 shares of CXW at an average $33.76, roughly $1,688,235, in a Form 4 filed 2026-08-18.
Grande Anthony L (EVP, Chief Development Officer at CoreCivic, Inc.) reported an open-market sale of 29,199 shares of CXW at an average $33.61, roughly $981,448, in a Form 4 filed 2026-08-17.
PRANN JOHN R JR (Director at CoreCivic, Inc.) reported an open-market sale of 30,000 shares of CXW at an average $32.21, roughly $966,300, in a Form 4 filed 2026-08-14.
Lappin Harley G. (Director at CoreCivic, Inc.) reported an open-market sale of 25,032 shares of CXW at an average $32.98, roughly $825,567, in a Form 4 filed 2026-08-14.
Murphy Devin Ignatius (Director at CoreCivic, Inc.) reported an open-market sale of 8,098 shares of CXW at an average $33.79, roughly $273,631, in a Form 4 filed 2026-08-12.
Mayberry Lucibeth (EVP, Chief Innovation Officer at CoreCivic, Inc.) reported an open-market sale of 120,000 shares of CXW at an average $33.29, roughly $3,994,800, in a Form 4 filed 2026-08-12.
Government agencies need detention facility bed capacity and have $70B in recent funding. CoreCivic has 20,000+ idle beds ready for immediate use. Benchmark analyst assigns 80% probability to facility sales with $36 price target (30% upside from $30.50), supported by recent strong earnings beat and raised guidance.
End of results.